Clinical Trial Update: Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating bevacizumab plus interleukin-2 in metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: UNKNOWN